Our Pricing

Saxenda vs Wegovy: Which Weight Loss Injection Is Right for You?

Choosing between Saxenda vs Wegovy can feel overwhelming when both are proven weight loss injections available in the UK. As a registered UK pharmacy, we've guided thousands of patients through this decision, and the right choice depends on your weight loss goals, budget, and how each medication fits your lifestyle. Both are prescription-only GLP-1 receptor agonists, but they differ significantly in active ingredient, dosing frequency, clinical efficacy, and cost.

Saxenda vs Wegovy: Key Differences Explained

When comparing Saxenda vs Wegovy, the most fundamental difference lies in their active ingredients and dosing schedules. Saxenda contains liraglutide, a GLP-1 receptor agonist administered daily via subcutaneous injection, whilst Wegovy contains semaglutide, a longer-acting GLP-1 analogue injected once weekly [1]. Both medications work by mimicking the incretin hormone GLP-1, which regulates appetite and blood sugar, but semaglutide has a significantly longer half-life, allowing for less frequent dosing.

Clinical trial data reveals notable differences in weight loss outcomes between the two treatments. The STEP 1 trial demonstrated that Wegovy users achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. In contrast, the SCALE Obesity and Prediabetes trial showed Saxenda users lost an average of 8.0% body weight over 56 weeks versus 2.6% with placebo [3]. Whilst both medications produce clinically significant weight loss, Wegovy consistently demonstrates superior efficacy in head-to-head comparisons, though individual responses vary considerably.

Cost represents another crucial factor in the Saxenda vs Wegovy decision. At Cured Pharmacy, Saxenda is available from £69.00 per pen, whilst Wegovy starts from £69.00 per pen, both subject to clinical assessment by our UK-registered prescribers. The daily dosing requirement of Saxenda means patients typically use one pen every 6 days at maintenance dose (3.0mg), whilst Wegovy's weekly administration can offer greater convenience despite the higher per-pen cost.

How Saxenda vs Wegovy Work for Weight Loss

Understanding the mechanism of action helps clarify why Saxenda vs Wegovy comparisons matter for treatment selection. Both medications are GLP-1 receptor agonists that bind to GLP-1 receptors in the brain's appetite centres, particularly the hypothalamus, reducing hunger signals and increasing satiety after meals [4]. This leads to reduced caloric intake without the need for extreme dietary restriction, though a balanced diet and regular physical activity enhance results.

The pharmacokinetic profiles differ substantially between liraglutide and semaglutide. Liraglutide in Saxenda reaches peak plasma concentration within 8-12 hours and has an elimination half-life of approximately 13 hours, necessitating daily administration to maintain therapeutic levels [1]. Semaglutide in Wegovy, by contrast, has a half-life of approximately 7 days due to structural modifications that slow degradation and renal clearance, enabling once-weekly dosing whilst maintaining stable blood levels throughout the week [2].

Both treatments also slow gastric emptying, which prolongs the feeling of fullness after eating and helps reduce between-meal snacking. Clinical experience at our pharmacy shows that patients often report reduced food cravings and better portion control within the first few weeks of treatment with either medication, though the onset and intensity of appetite suppression can vary individually.

GLP-1 Receptor Activation and Metabolic Benefits

Beyond appetite suppression, the Saxenda vs Wegovy comparison reveals shared metabolic benefits stemming from GLP-1 receptor activation. Both medications improve glycaemic control by enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon release, which can benefit patients with prediabetes or type 2 diabetes alongside obesity [3]. Additionally, GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, with semaglutide specifically showing reduced risk of major adverse cardiovascular events in the SELECT trial [5].

Saxenda vs Wegovy: Dosing and Administration Comparison

The dosing schedules for Saxenda vs Wegovy differ markedly and influence patient preference and adherence. Saxenda follows a daily escalation protocol starting at 0.6mg and increasing weekly by 0.6mg increments until reaching the maintenance dose of 3.0mg daily [1]. Each Saxenda pen contains 18mg of liraglutide, delivering 30 doses at the 0.6mg level or 6 doses at the maximum 3.0mg dose, meaning patients at maintenance typically require one pen every six days.

Wegovy uses a once-weekly injection schedule with a gradual dose escalation over 16-20 weeks: starting at 0.25mg weekly, then increasing to 0.5mg, 1.0mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [2]. Each Wegovy pen is pre-filled with a single dose, simplifying administration and reducing dosing errors. The weekly schedule often proves more convenient for patients with busy lifestyles, though some individuals prefer the flexibility of daily dosing to manage side effects.

Both medications are administered via subcutaneous injection into the abdomen, thigh, or upper arm using pre-filled pens with fine needles. Our clinical team provides comprehensive injection technique training during the consultation process, and most patients report minimal discomfort. Injection site rotation is recommended to prevent lipodystrophy, and neither medication requires refrigeration after first use, though unopened pens should be stored between 2-8°C.

Side Effects: Saxenda vs Wegovy Safety Profile

When evaluating Saxenda vs Wegovy for safety, both medications share a similar side effect profile characteristic of GLP-1 receptor agonists, with gastrointestinal symptoms being most common. Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort affect 20-50% of users, typically occurring during dose escalation and often diminishing over 4-8 weeks as tolerance develops [1][2]. Starting at a low dose and increasing gradually, as per the licensed protocols, significantly reduces the severity of these effects.

Clinical trial data suggests Wegovy may produce slightly higher rates of gastrointestinal side effects compared to Saxenda, likely due to the higher receptor occupancy achieved with semaglutide's longer half-life [3]. However, the once-weekly dosing of Wegovy can make managing these symptoms easier for some patients, as side effects tend to peak 1-3 days post-injection and then subside. With Saxenda's daily dosing, symptom patterns may feel more constant initially, though many patients report better day-to-day control once stabilised.

Both medications carry important safety warnings that our prescribers assess during consultation. Contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as GLP-1 agonists caused thyroid C-cell tumours in rodent studies (though no causal link has been established in humans) [4]. Pancreatitis, gallbladder disease, and severe gastrointestinal disease represent relative contraindications requiring careful clinical evaluation. All patients must be counselled on recognising symptoms of pancreatitis and instructed to discontinue treatment and seek immediate medical attention if severe abdominal pain develops.

Managing Side Effects with Either Treatment

Our pharmacists recommend several evidence-based strategies to minimise side effects regardless of whether you choose Saxenda or Wegovy. Eating smaller, more frequent meals rather than large portions, avoiding high-fat foods that delay gastric emptying further, staying well-hydrated, and taking the injection at a consistent time each day (or week) can all improve tolerability. If nausea persists beyond the first month or becomes severe, our clinical team can adjust the dose escalation schedule or consider anti-emetic support, always subject to prescriber approval.

Clinical Efficacy: Saxenda vs Wegovy Weight Loss Results

The clinical evidence comparing Saxenda vs Wegovy consistently demonstrates superior weight loss with semaglutide. In the pivotal STEP 1 trial, participants using Wegovy 2.4mg weekly achieved a mean weight reduction of 14.9% from baseline at 68 weeks, with 50.5% losing ≥15% body weight and 86.4% losing ≥5% [2]. The SCALE trial for Saxenda showed mean weight loss of 8.0% at 56 weeks, with 33.1% achieving ≥10% weight reduction and 63.2% losing ≥5% [3]. These differences are statistically significant and clinically meaningful for many patients.

However, individual response varies considerably, and some patients achieve excellent results with Saxenda whilst others may not tolerate Wegovy's higher potency. Factors influencing efficacy include baseline BMI, adherence to lifestyle modifications, genetic variations in GLP-1 receptor sensitivity, and concurrent medications. Our clinical experience shows that patients who combine either medication with structured dietary changes and regular physical activity consistently achieve better outcomes than those relying on pharmacotherapy alone.

Long-term weight maintenance represents a critical consideration in the Saxenda vs Wegovy comparison. The STEP 4 trial demonstrated that continued Wegovy treatment maintained weight loss, whilst discontinuation led to significant weight regain [5]. Similar patterns have been observed with Saxenda, emphasising that these medications work best as part of a long-term weight management strategy rather than short-term interventions. Our pharmacy team provides ongoing support to help patients sustain healthy behaviours alongside pharmacological treatment.

Cost and Value: Saxenda vs Wegovy UK Pricing

Evaluating Saxenda vs Wegovy from a cost perspective requires considering both per-pen pricing and monthly treatment costs based on dosing frequency. At Cured Pharmacy, Saxenda is available from £69.00 per pen, and since patients at the maintenance dose of 3.0mg daily typically use one pen every 6 days, the monthly cost approximates five pens. Wegovy starts from £69.00 per pen with weekly dosing, translating to approximately four pens monthly at the 2.4mg maintenance dose. Both treatments require an initial online consultation with our UK-registered prescribers, which is provided free of charge.

When comparing overall value in the Saxenda vs Wegovy decision, the superior weight loss efficacy of Wegovy may justify the higher per-pen cost for patients seeking maximum results, whilst Saxenda offers a more accessible entry point for those on tighter budgets or with lower BMI targets. We offer transparent upfront pricing before consultation, and our lowest price guarantee ensures competitive UK pricing on both medications. New patients can Save £20 off their first order using code Weightlossnew, making either treatment more affordable initially.

It's worth noting that neither Saxenda nor Wegovy is routinely available on NHS prescription for weight loss alone in most UK regions due to cost and capacity constraints, though some areas may provide access through specialist weight management services for patients meeting strict criteria. Private prescription through registered online pharmacies like Cured Pharmacy remains the primary access route for most UK patients seeking these treatments, with the convenience of next-day delivery and discreet packaging included.

Insurance and Payment Options

Some private medical insurance policies may cover GLP-1 medications for weight loss if prescribed for obesity-related comorbidities such as type 2 diabetes or cardiovascular risk reduction, though coverage varies significantly by provider and policy. We recommend checking with your insurer before starting treatment. Cured Pharmacy accepts all major payment methods and provides itemised receipts for insurance claims or tax purposes where applicable.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3-14. [accessed 15 August 2026]
5. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.